Sglt2 Inhibitor

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

Adults with type 2 diabetes who are referred to a clinical pharmacist are more likely to meet their HbA1c goal and receive appropriate medication management of comorbidities than people receiving usual care, according to a presenter.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

Treatment with sodium-glucose cotransporter-2 inhibitors significantly lowered risks for lupus nephritis, dialysis and kidney transplant for patients with systemic lupus erythematosus and type 2 diabetes, according to data.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.